样式: 排序: IF: - GO 导出 标记为已读
-
Inflammatory bowel disease and Clostridium difficile infection: clinical presentation, diagnosis, and management. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-11-28 Mei Bai,Hong Guo,Xiao-Yao Zheng
As a frequent complication of inflammatory bowel disease (IBD), Clostridium difficile infection (CDI) was confirmed to not only aggravate the symptoms of IBD but also result in unexpected outcomes, including death. With the increasing prevalence rate of IBD and the updating of CDI diagnosis, the incidence of CDI in IBD patients is also seen rising. Although a detection method consisting of glutamate
-
IBD barriers across the continents - East Asia. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-11-22 Joyce Wing Yan Mak,Agnes Hiu Yan Ho,Siew Chien Ng
Inflammatory bowel diseases (IBDs) are chronic illnesses with significant morbidities and impact on patients' quality of life. There has been a rapid increase in the incidence of IBD in East Asia in recent decades. However, there is a huge unmet need in the diagnosis and management of IBD in this region. With the increasing awareness of IBD in East Asia and a persistently high rate of tuberculosis
-
Association between IL-6 and prognosis of gastric cancer: a retrospective study. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-11-17 Panping Liang,Yuexin Zhang,Tianyuchen Jiang,Tao Jin,Zhengwen Chen,Zedong Li,Zehua Chen,Fengjun He,Jiankun Hu,Kun Yang
Background Gastric cancer (GC) is one of the common and fatal cancers. Even though the Tumor, Node, Metastasis (TNM) staging system is the most classical staging system recognized worldwide, it has been controversial because there are various factors affecting the prognosis of GC patients. Objectives The study aims to evaluate the relationship between interleukin-6 (IL-6) and several clinical indicators
-
Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-11-15 Camilla de Almeida Martins,Matheus Freitas Cardoso de Azevedo,Alexandre Sousa Carlos,Aderson Omar Mourão Cintra Damião,Carlos Walter Sobrado Junior,Sergio Carlos Nahas,Natália Sousa Freitas Queiroz
Background Biological therapies have revolutionized the treatment of patients with inflammatory bowel disease (IBD). Infliximab (IFX) has been shown to be effective in inducing and maintaining remission in patients with Crohn's disease and ulcerative colitis. However, about one-third of the patients are primary non-responders, and up to half can lose response over time. Hence, it is important to assess
-
Peptic ulcer disease burden, trends, and inequalities in 204 countries and territories, 1990-2019: a population-based study. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-11-14 Zhongmian Zhang,Weitian Yan,Xiyan Zhang,Jiaqi Wang,Zhonghan Zhang,Zili Lin,Lan Wang,Jiaqin Chen,Daming Liu,Wen Zhang,Zhihong Li
Background Peptic ulcer disease has been a major threat to the world's population, which remains a significant cause of hospitalization worldwide and healthcare resource utilization. Objectives We aimed to describe the global burden, trends, and inequalities of peptic ulcer disease. Design An observational study was conducted. Methods In this secondary analysis of the Global Burden of Disease, Injuries
-
Endoscopic characterization of neoplastic and non-neoplastic lesions in inflammatory bowel disease: systematic review in the era of advanced endoscopic imaging. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-11-10 Andrea Cassinotti,Marco Parravicini,Thomas P Chapman,Marco Balzarini,Lorenzo Canova,Simone Segato,Valentina Zadro,Simon Travis,Sergio Segato
Background Current guidelines strongly recommend the use of validated classifications to support optical diagnosis of lesions with advanced endoscopic imaging in the lower gastrointestinal tract. However, the optimal strategy in inflammatory bowel disease (IBD) is still a matter of debate. Objectives To analyze the accuracy of endoscopic classifications or single predictors for in vivo lesion characterization
-
Associations of sugar-sweetened beverages, artificially sweetened beverages, and natural juices with cardiovascular disease and all-cause mortality in individuals with inflammatory bowel disease in a prospective cohort study. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-11-08 Lintao Dan,Tian Fu,Yuhao Sun,Xixian Ruan,Shiyuan Lu,Jie Chen,Xiaoyan Wang
Background Beverage consumption was found to be associated with cardiovascular disease and mortality in the general population. However, it is unclear whether this association still exists in individuals with inflammatory bowel disease (IBD). Objectives To investigate the associations of sugar-sweetened beverages, artificially sweetened beverages, and natural juices with cardiovascular disease and
-
U-Net deep learning model for endoscopic diagnosis of chronic atrophic gastritis and operative link for gastritis assessment staging: a prospective nested case-control study. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-11-02 Quchuan Zhao,Qing Jia,Tianyu Chi
Background The operative link for the gastritis assessment (OLGA) system can objectively reflect the stratification of gastric cancer risk in patients with chronic atrophic gastritis (CAG). Objectives We developed a real-time video monitoring model for the endoscopic diagnosis of CAG and OLGA staging based on U-Net deep learning (DL). To further validate and improve its performance, we designed a study
-
Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-11-02 Youwen Zhu,Kun Liu,Hong Zhu,Haijun Wu
Background Nivolumab plus chemotherapy (NC) was recently approved as the first-line intervention for human epidermal growth factor receptor 2-negative advanced gastric/gastroesophageal junction cancer (GC/GEJC). Moreover, in the latest KEYNOTE-859 (NCT03675737), pembrolizumab plus chemotherapy (PC) was demonstrated to produce remarkable patient survival outcomes. Objectives The clinicians and patients
-
Portal hypertension increases the risk of hepatic decompensation after 90Yttrium radioembolization in patients with hepatocellular carcinoma: a cohort study. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-10-31 Laura Carrión,Ana Clemente-Sánchez,Laura Márquez-Pérez,Javier Orcajo-Rincón,Amanda Rotger,Enrique Ramón-Botella,Manuel González-Leyte,Miguel Echenagusía-Boyra,Arturo Luis Colón,Laura Reguera-Berenguer,Rafael Bañares,Diego Rincón,Ana Matilla-Peña
Background Transarterial radioembolization (TARE) is increasingly used in patients with hepatocellular carcinoma (HCC). This treatment can induce or impair portal hypertension, leading to hepatic decompensation. TARE also promotes changes in liver and spleen volumes that may modify therapeutic decisions and outcomes after therapy. Objectives We aimed to investigate the impact of TARE on the incidence
-
Optimal liver drainage rate for survival in patients with unresectable malignant hilar biliary obstruction using 3D-image volume analyzer. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-10-27 Kosaku Morimoto,Kazuyuki Matsumoto,Taisuke Obata,Takashi Oda,Kazuya Miyamoto,Akihiro Matsumi,Hiroyuki Terasawa,Yuki Fujii,Tatsuhiro Yamazaki,Shigeru Horiguchi,Koichiro Tsutsumi,Hironari Kato,Motoyuki Otsuka
Background Drainage exceeding 50% of total liver volume is a beneficial prognostic factor in patients with unresectable malignant hilar biliary obstruction (UMHBO). However, it is unclear what threshold percentage of total liver volume drained ('liver drainage rate') significantly improves survival in patients with UMHBO who received systemic chemotherapy. Objectives We aimed to assess the optimal
-
A systematic review on diagnosis and treatment of gastrointestinal diseases by magnetically controlled capsule endoscopy and artificial intelligence. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-10-27 Xiaotong Wang,Xiaoming Hu,Yongxue Xu,Jiahao Yong,Xiang Li,Kaixuan Zhang,Tao Gan,Jinlin Yang,Nini Rao
Background Magnetically controlled capsule endoscopy (MCCE) is a non-invasive, painless, comfortable, and safe equipment to diagnose gastrointestinal diseases (GID), partially overcoming the shortcomings of conventional endoscopy and wireless capsule endoscopy (WCE). With advancements in technology, the main technical parameters of MCCE have continuously been improved, and MCCE has become more intelligent
-
Moving scope technique improves technical success rate of device insertion during EUS-guided hepaticogastrostomy (with video). Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-10-25 Kimi Bessho,Takeshi Ogura,Saori Ueno,Atsushi Okuda,Nobu Nishioka,Jun Sakamoto,Yoshitaro Yamamoto,Yuki Uba,Mitsuki Tomita,Nobuhiro Hattori,Junichi Nakamura,Hiroki Nishikawa
Background Technical tips for device insertion during endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) have not been reported. To improve the technical success rate of device insertion without unnecessary tract dilation, the pushing force should be transmitted directly from the channel of the echoendoscope to the intrahepatic bile duct. Objectives We developed a novel technique, termed the
-
Gut microbiota interacts with inflammatory responses in acute pancreatitis. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-10-10 Linjun Wu,Jing Hu,Xiaolin Yi,Jianqin Lv,Jiaqi Yao,Wenfu Tang,Shu Zhang,Meihua Wan
Acute pancreatitis (AP) is one of the most common acute abdominal conditions, and its incidence has been increasing for years. Approximately 15-20% of patients develop severe AP (SAP), which is complicated by critical inflammatory injury and intestinal dysfunction. AP-associated inflammation can lead to the gut barrier and function damage, causing dysbacteriosis and facilitating intestinal microbiota
-
Clinical utility of colon capsule endoscopy: a moving target? Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-10-09 Gohar Jalayeri Nia,Ramesh P Arasaradnam,Anastasios Koulaouzidis
The purpose of this article is to provide an overview of white light colon capsule endoscopy's current clinical application, concentrating on its most recent developments. Second-generation colon capsule endoscopy (CCE2) is approved by the FDA for use as an adjunctive test in patients with incomplete colonoscopy and within Europe in patients at average risk, those with incomplete colonoscopies or those
-
Linked color imaging versus white light imaging in the diagnosis of colorectal lesions: a meta-analysis of randomized controlled trials. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-10-04 Yining Sun,Xiu-He Lv,Xian Zhang,Jin Wang,Huimin Wang,Jin-Lin Yang
Background Miss rate of colorectal neoplasia is associated with lesion histology, size, morphology, or location. Objectives We aim to compare the efficacy of Linked color imaging (LCI) versus white light imaging (WLI) for adenoma detection rate (ADR), the detection of sessile serrated lesions (SSLs), serrated lesions (SLs), advanced adenomas (AAs), diminutive lesions (DLs), and flat lesions (FLs) by
-
10 years of biologic use patterns in patients with inflammatory bowel disease: treatment persistence, switching and dose intensification - a nationwide population-based study. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-09-29 Hee Moon Koo,Yu Kyung Jun,Yonghoon Choi,Cheol Min Shin,Young Soo Park,Nayoung Kim,Dong Ho Lee,Young Kee Shin,Hyuk Yoon
Background Treatments for inflammatory bowel diseases (IBD) have evolved in the era of biologics. However, the real-world data on their usage patterns and sequencing are still limited. Objectives We aimed to investigate treatment persistence and dose intensification of first- and second-line biologics in patients with IBD. Design In this retrospective, cohort study using nationwide claims data, 13
-
The new normal: a review of the impact of COVID-19 on gastroenterology fellowship training. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-09-28 Salima Makhani,Jaclyn Morales,Matthew J Whitson
The COVID-19 pandemic had a significant impact on medical education and gastroenterology fellowship training. As a result of the pandemic, a trainee's physical safety, mental health and wellness, clinical and procedural training, and educational opportunities were all potentially altered. Changes necessitated at the start of the pandemic were different than those needed further along in the pandemic
-
Crohn-like disease long remission in a pediatric patient with glycogen storage disease type Ib treated with empagliflozin: a case report. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-09-28 Margherita Calia,Andrea Mario Luciano Arosio,Viola Crescitelli,Anna Fornari,Roberta Pretese,Serena Gasperini,Giovanna Zuin
Glycogen storage disease type Ib (GSD Ib) is a rare hereditary glycogen disorder that results in inadequate maintenance of glucose homeostasis, accumulation of glycogen in different organs, loss and dysfunction of neutrophils. Crohn's-like disease is observed in up to 24-77% of GDS Ib cases. Recently, empagliflozin has been recommended as a treatment for neutrophil dysfunction in GDS Ib patients with
-
A nomogram incorporating ileal and anastomotic lesions separately to predict the long-term outcome of Crohn's disease after ileocolonic resection. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-09-14 Shanshan Xiong,Jinshen He,Baili Chen,Yao He,Zhirong Zeng,Minhu Chen,Zhihui Chen,Yun Qiu,Ren Mao
Background The Rutgeerts score (RS) is widely used to predict postoperative recurrence after ileocolonic resection for Crohn's disease (CD) based on the severity of lesions at the neoterminal ileum and anastomosis (RS i0-i4). However, the value of anastomotic ulcers remains controversial. Objectives Our aim was to establish a nomogram model incorporating ileal and anastomotic lesions separately to
-
Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-09-11 Rosanne W Meijboom,Helga Gardarsdottir,Matthijs L Becker,Kris L L Movig,Johan Kuijvenhoven,Toine C G Egberts,Thijs J Giezen
Background Many patients with inflammatory bowel disease (IBD) have transitioned from an infliximab originator to a biosimilar. However, some patients retransition to the originator (i.e. stop biosimilar and reinitiate the originator). Whether this sign of potential unsatisfactory treatment response is specifically related to the infliximab biosimilar or the patient and/or the disease including patients'
-
NOD-like receptors mediate homeostatic intestinal epithelial barrier function: promising therapeutic targets for inflammatory bowel disease. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-09-09 Feng Zhou,Guo Dong Zhang,Yang Tan,Shi An Hu,Qun Tang,Gang Pei
Inflammatory bowel disease (IBD) is a chronic gastrointestinal inflammatory disease that involves host genetics, the microbiome, and inflammatory responses. The current consensus is that the disruption of the intestinal mucosal barrier is the core pathogenesis of IBD, including intestinal microbial factors, abnormal immune responses, and impaired intestinal mucosal barrier. Cumulative data show that
-
IBD barriers across the continents: a continent-specific analysis - Australasia. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-09-08 Alexander T Elford,Rupert W Leong,Emma P Halmos,Manal Morgan,Kate Kilpatrick,Peter J Lewindon,Richard B Gearry,Britt Christensen
Australasia, encompassing Australia, New Zealand, and Papua New Guinea, has some of the highest prevalence's of inflammatory bowel disease (IBD) in the world. The way IBD medicine is practiced varies between and within these countries. There are numerous shared issues of IBD care between Australia and New Zealand, whereas Papua New Guinea has its' own unique set of circumstances. This review looks
-
Inflammation in the proximal colon is a risk factor for the development of colorectal neoplasia in inflammatory bowel disease patients with primary sclerosing cholangitis. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-09-07 Omar K Jamil,Dustin Shaw,Zifeng Deng,Nicholas Dinardi,Natalie Fillman,Shivani Khanna,Noa Krugliak Cleveland,Atsushi Sakuraba,Christopher R Weber,Russell D Cohen,Sushila Dalal,Bana Jabri,David T Rubin,Joel Pekow
Background Patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) have an increased risk of developing colorectal neoplasia (CRN) in the proximal colon. Objectives To evaluate whether duration and severity of inflammation are linked to the development of CRN in this population. Design Retrospective, case-control chart review of patients with PSC and IBD at a tertiary
-
Update on the second-line treatment of Helicobacter pylori infection: a narrative review. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-09-04 Chih-An Shih,Chang-Bih Shie,Wei-Chen Tai,Seng-Kee Chuah,Hsi-Chang Lee,Ping-I Hsu
A standard bismuth quadruple therapy, a fluoroquinolone-containing triple (or quadruple) therapy or a proton pump inhibitor (PPI)-amoxicillin high-dose dual therapy has been recommended as a second-line treatment for Helicobacter pylori infection by the Maastricht VI/Florence Consensus Report. The major shortcoming of levofloxacin-amoxicillin triple therapy is low cure rate for eradicating levofloxacin-resistant
-
Empirical versus tailored therapy based on genotypic resistance detection for Helicobacter pylori eradication: a systematic review and meta-analysis. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-31 Meng Li,Xiaolei Wang,Wenting Meng,Yun Dai,Weihong Wang
Background The eradication rate of Helicobacter pylori infection with empirical therapy has decreased due to increased drug resistance. The latest guidelines recommend genotypic resistance-guided therapy, but its clinical efficacy remains unclear. Objectives The purpose of our study was to evaluate whether tailored therapy based on genotypic resistance is superior to empirical therapy for H. pylori
-
Handgrip strength and risk of malnutrition are associated with an increased risk of hospitalizations in inflammatory bowel disease patients. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-31 Katherine Bedard,Lorian Taylor,Naheed Rajabali,Karen Kroeker,Brendan Halloran,Guanmin Meng,Maitreyi Raman,Puneeta Tandon,Juan G Abraldes,Farhad Peerani
Background In patients with inflammatory bowel disease (IBD), frailty is independently associated with mortality and morbidity. Objectives This study aimed to extend this work to determine the association between the clinical frailty scale (CFS), handgrip strength (HGS), and malnutrition with IBD-related hospitalizations and surgeries. Design IBD patients ⩾18 years of age were prospectively enrolled
-
Liver impaction technique improves technical success rate of guidewire insertion during EUS-guided hepaticogastrostomy (with video). Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-31 Junichi Nakamura,Takeshi Ogura,Saori Ueno,Atsushi Okuda,Nobu Nishioka,Yuki Uba,Mitsuki Tomita,Kimi Bessho,Nobuhiro Hattori,Hiroki Nishikawa
Background If the guidewire becomes kinked by the needle, guidewire manipulation may be difficult, and can cause complications such as guidewire shearing or injury during endoscopic ultrasound (EUS)-guided hepaticogastrostomy (HGS). To overcome this matter, we have previously described a technical tip for preventing guidewire injury, termed 'liver impaction technique'. However, its technical feasibility
-
Planning to conceive within a year is associated with better pregnancy-specific disease-related patient knowledge and better medication adherence in women of childbearing age with inflammatory bowel disease. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-30 Christian P Selinger,Robyn Laube,Helen Steed,Matthew Brookes,Nihr BioResource,Rupert W L Leong
Background Adherence to inflammatory bowel disease (IBD) medication is crucial to maintain remission, especially during pregnancy. Objective To examine the influence of family planning and pregnancy-related patient knowledge regarding IBD and pregnancy on adherence. Design Cross-sectional survey study. Methods We surveyed female patients with IBD aged 18-35 years, who at recruitment to the UK IBD BioResource
-
Efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori first-line treatment: a single-center, randomized, controlled trial. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-30 Xiaolei Wang,Guigen Teng,Xinhong Dong,Yun Dai,Weihong Wang
Background With the increase in antibiotic resistance, the success rate of Helicobacter pylori (H. pylori) eradication therapy has declined in recent years. Vonoprazan-amoxicillin (VA) dual therapy has been reported to be a promising regimen. Objectives To compare the efficacy and safety of VA dual therapy and bismuth quadruple therapy containing amoxicillin and clarithromycin for H. pylori first-line
-
At admission hemodynamic instability is associated with increased mortality and rebleeding rate in acute gastrointestinal bleeding: a systematic review and meta-analysis. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-30 Edina Tari,Levente Frim,Tünde Stolcz,Brigitta Teutsch,Dániel Sándor Veres,Péter Hegyi,Bálint Erőss
Background Acute gastrointestinal bleeding (GIB) is a life-threatening event. Around 20-30% of patients with GIB will develop hemodynamic instability (HI). Objectives We aimed to quantify HI as a risk factor for the development of relevant end points in acute GIB. Design A systematic search was conducted in three medical databases in October 2021. Data sources and methods Studies of GIB patients detailing
-
Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn's disease. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-30 Nathalie Van den Berghe,Dahham Alsoud,Bram Verstockt,Séverine Vermeire,Paul Declerck,Debby Thomas
Background Since not all Crohn's disease (CD) patients respond adequately to ustekinumab therapy, biomarkers could aid to monitor treatment response and optimize therapeutic outcomes. Objectives To explore the dynamics of serum biomarker concentrations to monitor the response to ustekinumab treatment in CD patients. Design Retrospective, exploratory study to evaluate concentrations of serum cytokines
-
Effects of Crohn's disease exclusion diet on remission: a systematic review. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-30 Zhanhui Zhu,Yang Lei,Zheng Lin
Background Dietary therapy may potentially reduce inflammation and promote mucosal healing in patients with Crohn's disease and is associated with fewer side effects and lower cost compared to medical therapy. Recently the Crohn's disease exclusion diet (CDED) has been developed to reduce exposure to individualized dietary components which negatively affect the intestine in patients with Crohn's disease
-
Rights and wrongs of Helicobacter pylori testing and treatment in children. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-26 Toshihiko Kakiuchi
-
Adequate amounts of probiotics increase the success rate of Helicobacter pylori eradication therapy in children. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-24 Toshihiko Kakiuchi
-
Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-24 Federico Argüelles-Arias,Teresa Valdés Delgado,Belén Maldonado Pérez,Jaime González Antuña,Luisa Castro Laria
Background Ustekinumab (UST) is indicated for the treatment of Crohn's disease (CD) and Ulcerative Colitis (UC). Despite having shown clinical effectiveness in the real world, some patients may lose response over time or need a higher dose to achieve it. In this context, UST intravenous (IV) maintenance has been proposed. Objectives The primary endpoint of our study was to evaluate the efficacy and
-
Comparison of high-flow nasal cannula and conventional nasal cannula during sedation for endoscopic submucosal dissection: a retrospective study. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-24 Seungwon Lee,Ji Won Choi,In Sun Chung,Duk Kyung Kim,Woo Seog Sim,Tae Jun Kim
Background The high-flow nasal cannula (HFNC) is a relatively recent method that provides high-flow, heated, humidified gas delivery. Objectives We compared HFNC (group HF) and conventional nasal cannula (NC) (group CO) during deep sedation with propofol and remifentanil for endoscopic submucosal dissection (ESD). Design Single-center, retrospective observational cohort study. Methods In this study
-
Effectiveness and tolerability of methotrexate monotherapy in Crohn's disease patients: a multicenter observational study. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-23 Jihye Park,Jaeyoung Chun,Soo Jung Park,Jae Jun Park,Tae Il Kim,Hyuk Yoon,Jae Hee Cheon
Background Methotrexate monotherapy is recommended as a maintenance therapy for Crohn's disease (CD). However, long-term follow-up data are scarce. Objectives We aimed to examine the effectiveness and tolerability of methotrexate monotherapy in 94 CD patients from three inflammatory bowel disease Clinics in Korea. Design This was a multicenter retrospective observational study. Methods Patients with
-
Comparison of early aggressive versus nonaggressive fluid resuscitation in acute pancreatitis: a meta-analysis. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-22 Jian Guo,Jiaze Hong,Yujing He,Qingyuan Li,Tongmin Huang,Dandi Lou,Jie Zhang
Background Early fluid resuscitation is one of the main therapeutic strategies for acute pancreatitis (AP). This study investigated the effects of early aggressive and nonaggressive hydration on AP. Objectives The aim of this meta-analysis is to investigate the differences between aggressive and nonaggressive intravenous fluid resuscitation in AP. Design This study was based on publicly available data
-
Presence of risk factors associated with colectomy among patients with ulcerative colitis: a post hoc analysis of data from the tofacitinib OCTAVE ulcerative colitis clinical program. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-07 David T Rubin,Leonardo Salese,Mitchell Cohen,Paulo G Kotze,John C Woolcott,Chinyu Su,Rajiv Mundayat,Jerome Paulissen,Joana Torres,Millie D Long
Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Objective To assess colectomy incidence rates (IRs) and baseline characteristics for the presence of identified colectomy risk factors among patients in the tofacitinib OCTAVE UC clinical program. Design This post hoc analysis evaluated patients in the 8-week OCTAVE Induction 1 and
-
Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX versus 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-08-01 Brigida Barberio,Ilaria Marsilio,Andrea Buda,Luisa Bertin,Gianluca Semprucci,Annalisa Zanini,Martina Crepaldi,Fabiana Zingone,Edoardo Savarino
Background Low bioavailability steroids, including beclomethasone dipropionate (BDP) and budesonide MMX, have been developed to ensure colonic targeting and low systemic activity than systematic corticosteroids in treating patients with ulcerative colitis (UC). Objectives This systematic review and meta-analysis evaluated the efficacy and safety of BDP and budesonide MMX® compared with 5-aminosalicylic
-
A nomogram based on clinical factors to predict calendar year readmission in patients with ulcerative colitis. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-07-31 Ying Xiang,Ying Yuan,Jinyan Liu,Xinwen Xu,Zhenyu Wang,Shahzeb Hassan,Yue Wu,Qi Sun,Yonghua Shen,Lei Wang,Hua Yang,Jing Sun,Guifang Xu,Qin Huang
Background Readmission shortly after discharge is indicative of an increased disease severity for patients with ulcerative colitis (UC) and ineffectiveness to medical therapy, which may contribute to a dismal prognosis. Objectives This study aimed to explore prognostic variables with a nomogram to predict unplanned UC-related readmission within 1 year after discharge. Design A retrospective cohort
-
The progression of hepatorenal syndrome-acute kidney injury in acute alcohol-associated hepatitis: renal outcomes after liver transplant. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-07-31 Alessandro Colletta,Katherine M Cooper,Deepika Devuni
Background Hepatorenal syndrome-acute kidney injury (HRS-AKI) is a complication of advanced liver disease in patients with ascites and circulatory dysfunction. Little data remain on the relationship between HRS-AKI outcomes and different etiologies of liver disease post-liver transplant (LT). Objectives The primary aim was to evaluate the effect of HRS-AKI on renal outcomes in patients with acute alcohol-associated
-
COVID-19 in patients with liver disease and liver transplant: clinical implications, prevention, and management. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-07-25 Gabriel Perreault,Charlotte Ching,Yael R Nobel
The coronavirus disease 2019 (COVID-19) pandemic has had enormous implications for the care of patients with chronic liver disease (CLD), cirrhosis, and liver transplant (LT). Clinical outcomes of COVID-19 vary in patients with CLD and cirrhosis compared to healthy controls, and in patients with LT compared to patients without LT. Several special considerations apply to the approach to vaccination
-
Endoscopic ultrasound drainage of pancreatic fluid collections: do we know enough about the best approach? Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-07-16 Andrada Seicean,Cristina Pojoga,Voicu Rednic,Claudia Hagiu,Radu Seicean
Pancreatic fluid collection often occurs as a local complication of acute pancreatitis, and drainage is indicated in symptomatic patients. The drainage may be surgical, percutaneous, or endoscopic ultrasound (EUS) guided. In symptomatic collections older than 4 weeks and localized in the upper abdomen, EUS-guided drainage is the first choice of treatment. Lumen-apposing metal stents are useful in cases
-
Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-07-14 Tamás Resál,Péter Bacsur,Miklós Horváth,Kata Szántó,Mariann Rutka,Anita Bálint,Anna Fábián,Renáta Bor,Zoltán Szepes,János Fekete,Klaudia Farkas,Pál Miheller,Tamás Molnár
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has complicated the management of inflammatory bowel diseases (IBD). Objectives This study aimed to assess the efficacy of different anti-SARS-CoV-2 vaccines under different treatments in IBD patients and identify predictive factors associated with lower serological response, including anti-tumor necrosis factor (anti-TNF)
-
Challenges in the diagnosis and management of IBD: a sub-Saharan African perspective. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-07-12 Gill Watermeyer,Leolin Katsidzira,Bright Nsokolo,Olusegun Isaac Alatise,Babatunde M Duduyemi,Chris Kassianides,Phoebe Hodges
With the exception of South Africa, inflammatory bowel disease (IBD) has long been considered uncommon in sub-Saharan Africa (SSA) with a dearth of peer-reviewed publications from the subcontinent. This most likely reflects underreporting as some cases may be missed due to the high burden of infectious diseases which may closely mimic IBD. In addition, many countries in SSA have limited endoscopic
-
Pilot study on a new endoscopic platform for colorectal endoscopic submucosal dissection. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-07-11 Roberta Maselli,Marco Spadaccini,Piera Alessia Galtieri,Matteo Badalamenti,Elisa Chiara Ferrara,Gaia Pellegatta,Antonio Capogreco,Silvia Carrara,Andrea Anderloni,Alessandro Fugazza,Cesare Hassan,Alessandro Repici
Background The endoscopic submucosal dissection (ESD) is a technically demanding and time-consuming procedure, with an increased risk of adverse events compared to standard endoscopic resection techniques. The main difficulties are related to the instability of the operating field and to the loss of traction. We aimed to evaluate in a pilot trial a new endoscopic platform [tissue retractor system (TRS);
-
Clinical impact of videocapsule endoscopy and device-assisted enteroscopy in non-bleeding small bowel lesions. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-07-07 Matilde Topa,Nicoletta Nandi,Lucia Scaramella,Michele Puricelli,Marco Pennazio,Reena Sidhu,David S Sanders,Gian Eugenio Tontini,Roberto Penagini,Maurizio Vecchi,Luca Elli
Background Videocapsule endoscopy (VCE) and double-balloon enteroscopy (DBE) are part of the diagnostic and therapeutic work-up of indications other than suspected small bowel bleeding (OSBB). The literature is currently lacking studies describing these procedures in this particular setting. Objectives We assessed the clinical impact of VCE and DBE in a large monocentric cohort of OSBB patients, as
-
Active tuberculosis in inflammatory bowel disease patients: a case-control study. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-07-04 Matheus Freitas Cardoso de Azevedo,Luísa Leite Barros,Filipe Fernandes Justus,Jane Oba,Karoline Soares Garcia,Camilla de Almeida Martins,Alexandre de Sousa Carlos,André Zonetti Arruda Leite,Aytan Miranda Sipahi,Natália Sousa Freitas Queiroz,Adérson Omar Mourão Cintra Damião
Background/Aims Anti-tumor necrosis factor (anti-TNF) drugs have been the mainstay therapy for moderate to severe inflammatory bowel disease (IBD) over the past 25 years. Nevertheless, these drugs are associated with serious opportunistic infections like tuberculosis (TB). Brazil is ranked among the 30 countries with the highest incidence of TB in the world. This study aimed at identifying risk factors
-
Spatiotemporal analysis of small bowel capsule endoscopy videos for outcomes prediction in Crohn's disease. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-06-30 Raizy Kellerman,Amit Bleiweiss,Shimrit Samuel,Reuma Margalit-Yehuda,Estelle Aflalo,Oranit Barzilay,Shomron Ben-Horin,Rami Eliakim,Eyal Zimlichman,Shelly Soffer,Eyal Klang,Uri Kopylov
Background Deep learning techniques can accurately detect and grade inflammatory findings on images from capsule endoscopy (CE) in Crohn's disease (CD). However, the predictive utility of deep learning of CE in CD for disease outcomes has not been examined. Objectives We aimed to develop a deep learning model that can predict the need for biological therapy based on complete CE videos of newly-diagnosed
-
Esophageal secondary peristalsis following acid infusion and chemical clearance correlate with mucosal integrity and acid sensitivity in GERD patients. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-06-29 Ming-Wun Wong,Jui-Sheng Hung,Wei-Yi Lei,Tso-Tsai Liu,Chih-Hsun Yi,Shu-Wei Liang,Chandra Prakash Gyawali,Jen-Hung Wang,Chien-Lin Chen
Background Acid sensitivity can be altered in patients with gastroesophageal reflux disease (GERD). Secondary peristalsis helps clear gastro-esophageal refluxate and residual ingested food bolus. Objectives The aim of this study was to investigate the associations among acid sensitivity, esophageal mucosal integrity, chemical clearance, and secondary peristalsis before and after esophageal acid infusion
-
The effect of synbiotics in patients with NAFLD: a systematic review and meta-analysis. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-06-22 Jiacheng Cai,Jia Dong,Dahua Chen,Hua Ye
Background Nonalcoholic fatty liver disease (NAFLD) is the highest incidence of chronic liver disease worldwide, seriously endangering human health, and its pathogenesis is still unclear. In the recent years, increasing evidence has shown that intestinal flora plays an important role in the occurrence and development of NAFLD. Synbiotics can alter gut microbiota and may be a treatment option for NAFLD
-
Brief communication: global temporal trends in the efficacy of clarithromycin-based regimens for the treatment of Helicobacter pylori infection. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-06-22 Steven F Moss,William D Chey,Patrick Daniele,Corey Pelletier,Rinu Jacob,Gabriel Tremblay,Elizabeth Hubscher,Eckhard Leifke,Peter Malfertheiner
Background Helicobacter pylori eradication rates achieved with clarithromycin-based triple therapies are declining due to antibiotic resistance, but data regarding temporal changes in efficacy with these eradication therapies are scarce. Objective To evaluate the efficacy of clarithromycin-based triple eradication regimens over time. Design A comprehensive literature review and time-trend analysis
-
Because I'm happy - positive affect and its predictive value for future disease activity in patients with inflammatory bowel diseases: a retrospective cohort study. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-06-17 Brian M Lang,Martina Ledergerber,Sebastian Bruno Ulrich Jordi,Niklas Krupka,Luc Biedermann,Philipp Schreiner,Pascal Juillerat,Jacqueline Wyss,Stephan R Vavricka,Jonas Zeitz,Roland von Känel,Gerhard Rogler,Niko Beerenwinkel,Benjamin Misselwitz
Background While the detrimental impact of negative emotions on the clinical course of inflammatory bowel disease (IBD) and quality of life has been extensively investigated, evidence for a potential impact of positive emotions is scarce. Objectives We aim to analyse contributing factors of positive affect and their predictive value for disease course in IBD patients. Design In this retrospective cohort
-
Microscopic colitis is a risk factor for low bone density: a systematic review and meta-analysis. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-06-15 Anett Rancz,Brigitta Teutsch,Marie Anne Engh,Dániel Sándor Veres,László Földvári-Nagy,Bálint Erőss,Nóra Hosszúfalusi,Márk Félix Juhász,Péter Hegyi,Emese Mihály
Background Microscopic colitis (MC) is a chronic inflammatory disease of the large bowel characterized by watery diarrhea, substantially decreasing the patient's quality of life. Scarce data suggest that MC is associated with low bone density (LBD). Objectives We aimed to assess whether MC is a risk factor for LBD and the proportion of patients with MC having LBD. Design A systematic review and meta-analysis
-
Helicobacter pylori in children: think before you kill the bug! Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-06-15 M Ravikumara
Since the discovery of Helicobacter pylori (H. pylori) as the causative organism for gastric and duodenal ulcers four decades ago and subsequent recognition as class 1 gastric carcinogen, countless numbers of studies have been conducted and papers published, on the efficacy of various management strategies to eradicate the infection. In adults, a global consensus by the experts in the field concluded
-
Managing IBD in the COVID-19 era. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-06-15 Nicholas Scalzo,Ryan C Ungaro
Over the last 2 years the lives of millions have changed because of the emergence of Coronavirus disease 2019 (COVID-19). Patients living with inflammatory bowel disease (IBD) represent a sizable population with their own sets of challenges to providers in the wake of so much uncertainty. The Centers for Disease Control considers immunocompromised individuals at higher risk of infection and complications
-
Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-06-12 Christine Lee,Thomas Louie,Lindy Bancke,Beth Guthmueller,Adam Harvey,Paul Feuerstadt,Sahil Khanna,Robert Orenstein,Erik R Dubberke
Background Microbiota-based treatments reduce the incidence of recurrent Clostridioides difficile infections (rCDIs), but prospectively collected safety data needed to broaden patient access and protect public health have been limited. Objectives We provide cumulative safety data from five prospective clinical trials evaluating fecal microbiota, live-jslm (RBL) - the first microbiota-based live biotherapeutic
-
Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis. Therap. Adv. Gastroenterol. (IF 4.2) Pub Date : 2023-06-12 Michal Prokopič,Georgiana Gilca-Blanariux,Peter Lietava,Anca Trifan,Anna Pietrzak,Agata Ladic,Marko Brinar,Svetlana Turcan,Tamás Molnár,Peter Bánovčin,Milan Lukáš
Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic immune-mediated diseases with a high incidence and prevalence in Europe. Since these are diseases with associated disability, they require complex management and the availability of high-quality healthcare resources. We focused on the analysis of IBD care in selected countries of Central and Eastern Europe